RE:value It's worth 23¢ today in the market's opinion, Rosie. I'm not going to argue with that. Denali is in the same business as Bioasis, only more advanced, and they have been worth as much USD8 billion which would be CDN $140 or $150 per share for Bioasis.
But 23¢ seems fair for a company that hasn't accomplished much with the science for 14 years. We still don't know whether xB3 will achieve IND status, let alone be successful in humans. xB3 looks good but we just don't know the answers yet.
23¢. One for a quarter, three for a dime.
It'll break out at some point. The real fear is that Bioasis will likely be sold off for a couple of bucks by a BoD and executive who wants those cheap options to come home for them and a weary shareholder base that just wants to run away.
I think that enough shareholders will vote to allow a pharma to get this for buck or so. When I read in Zacks's view that the investment banker is working on "
accretive" merger or acquisition terms then I have to ask where Zacks got that notion, or information. Was it from from Bioasis or from Ladenburg Thalmann, some other involved party or did Zacks make it up. One thing for sure, Zacks has no dog in this hunt.
Accretive! That sounds like something akin to a CVR, as
KayakerBC discussed and
as I agreed.
Anyway, 23¢.
That's the story today.
jd